Cargando…

Serum Phospholipid Profile Changes in Gaucher Disease and Parkinson’s Disease

Alterations in the levels of serum sphingolipids and phospholipids have been reported in Gaucher disease and in Parkinson’s disease, suggesting a potential role of these lipids as biomarkers. This project’s objective is to detect novel associations and novel candidate biomarkers in the largest Spani...

Descripción completa

Detalles Bibliográficos
Autores principales:	López de Frutos, Laura, Almeida, Francisco, Murillo-Saich, Jessica, Conceição, Vasco A., Guma, Monica, Queheberger, Oswald, Giraldo, Pilar, Miltenberger-Miltenyi, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499334/ https://www.ncbi.nlm.nih.gov/pubmed/36142296 http://dx.doi.org/10.3390/ijms231810387

Ejemplares similares

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Parkinson disease in Gaucher disease
por: Rodriguez-Porcel, Federico, et al.
Publicado: (2017)

Identification of risk features for complication in Gaucher’s disease patients: a machine learning analysis of the Spanish registry of Gaucher disease
por: Andrade-Campos, Marcio M., et al.
Publicado: (2020)

Muscle-tendon weakness contributes to chronic fatigue syndrome in Gaucher’s disease
por: Roca-Espiau, Mercedes, et al.
Publicado: (2019)

Pathologic expansion in the C9orf72 gene is associated with accelerated decline of respiratory function and decreased survival in amyotrophic lateral sclerosis
por: Miltenberger-Miltenyi, Gabriel, et al.
Publicado: (2021)

Novel Management and Screening Approaches for Haematological Complications of Gaucher’s Disease
por: Giraldo, Pilar, et al.
Publicado: (2021)

Fabry Disease Therapy: State-of-the-Art and Current Challenges
por: Azevedo, Olga, et al.
Publicado: (2020)

Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneously
por: Noya, MSoledad, et al.
Publicado: (2018)

Parkinson’s Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees
por: Gago, Miguel Fernandes, et al.
Publicado: (2020)

Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula
por: Giraldo, Pilar, et al.
Publicado: (2012)

Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies?
por: Andrade-Campos, Marcio, et al.
Publicado: (2020)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Gaucher-Associated Parkinsonism
por: Li, Yaqiong, et al.
Publicado: (2015)

Fabry Disease and the Heart: A Comprehensive Review
por: Azevedo, Olga, et al.
Publicado: (2021)

Circulating Pro- and Anti-Inflammatory Metabolites and Its Potential Role in Rheumatoid Arthritis Pathogenesis
por: Coras, Roxana, et al.
Publicado: (2020)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

Recommendations on the follow‐up of patients with Gaucher disease in Spain: Results from a Delphi survey
por: Giraldo, Pilar, et al.
Publicado: (2022)

The Influence of Genetic Variability and Proinflammatory Status on the Development of Bone Disease in Patients with Gaucher Disease
por: Gervas-Arruga, Javier, et al.
Publicado: (2015)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

Social distancing, home-infusion and oral therapy: Evolving paradigms on Gaucher disease management in Spain during COVID-19 pandemic
por: Andrade-Campos, Marcio M., et al.
Publicado: (2021)

Rare Association of two Genetic Causes of Sudden Death in a Young Survivor
por: Brito, Dulce, et al.
Publicado: (2017)

Advantages of digital technology in the assessment of bone marrow involvement in Gaucher's disease
por: Valero-Tena, Esther, et al.
Publicado: (2023)

The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease
por: Kinghorn, Kerri J., et al.
Publicado: (2017)

The cognitive profile of type 1 Gaucher disease patients
por: Biegstraaten, Marieke, et al.
Publicado: (2012)

Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease
por: Galper, Jasmin, et al.
Publicado: (2021)

Rapid-Onset Dystonia and Parkinsonism in a Patient With Gaucher Disease
por: Hertz, Ellen, et al.
Publicado: (2023)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher’s Disease
Publicado: (1916)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease
por: Andrade-Campos, Marcio, et al.
Publicado: (2017)

Pathological looping in the synucleinopathies: investigating the link between Parkinson’s disease and Gaucher disease
por: Kinghorn, Kerri J.
Publicado: (2011)

Management goals of type 1 Gaucher disease in South Africa: An expert Delphi consensus document on good clinical practice
por: Louw, Vernon Johan, et al.
Publicado: (2023)

Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism
por: McMahon, Benjamin, et al.
Publicado: (2016)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Gaucher disease: an update
por: Dumitrascu, Dan L.
Publicado: (2021)

Gaucher Disease for Hematologists
por: Özdemir, Gül Nihal, et al.
Publicado: (2022)

Type I Gaucher disease with bullous pemphigoid and Parkinson disease: A case report
por: Le Peillet, Damien, et al.
Publicado: (2018)

GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches
por: Riboldi, Giulietta M., et al.
Publicado: (2019)

Parkinson’s disease in Gaucher disease patients: what’s changing in the counseling and management of patients and their relatives?
por: Di Rocco, Maja, et al.
Publicado: (2020)

Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease
por: Han, Tae-Un, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ccvbrcj1p1jcrckubbve7fpfp0